MONTREAL IS MOVING ON!!! đ”âȘïžđŽ
For the first time since 2021, the @CanadiensMTL have advanced to the Second Round of the #StanleyCup Playoffs!
Presented by @NavyFederal
Phase 3 LITESPARK-011: Belzutifan + Lenvatinib vs Cabozantinib in pretreated metastatic clear cell renal cancer #GU25 shows +ve PFS HR 0.75 , OS HR 0.85 (non-significant), âŹïž RR 53% vs 40%, G3+ TRAEs 72% vs 66%. Cabozantinib is hard to beat making this a standard of care. Using the most active drugs first rather than sequencing is debatable, but not all patients can sequence. We still donât have significant OS post in IO refractory RCC @OncoAlert
3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that itâs in a cisplatin ineligible population (accounting for the poor performance of the control arm). Itâs also a smaller trial. The control arm of KN-B15 performed slightly better than NIAGARA (Gem/cis for both), but the trials are otherwise similar. The pCR in the EVP trails and the consistent efficacy of EVP is striking. #GU26
Je suis sans mot.
50 ans dâexpertise en don dâorgane.
Fin du financement pour avril 2026 ⊠câest demain matin pour un processus aussi complexe!
Je vous recommande cet article de La Presse : « Des vies sont en jeu » https://t.co/pZHq40NiLS
đš Wow! #ASCO25@ASCO was absolutely massive!
10 @NEJM papers published simultaneously đ all practice-changing studies ! đŹâšđ§” See below for these studies đ@oncoalert
The curves everybodyâs been waiting for.
First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.